Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold ...

Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus ...

Edgewise Therapeutics , Inc., a biotechnology company specializing in pharmaceutical preparations, announced the promotion of ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...

So notwithstanding the buoyant share price, we think it's well worth asking whether Edgewise Therapeutics' cash burn is too risky. In this report, we will consider the company's annual negative free ...

For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share price soaring by 176%. Having said that, unprofitable companies are risky ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...